A. Szpechcinski

发表

miR-625-3p and lncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and Surgery

W. Lam, R. Stahel, Ferdinando Cerciello, 2019, Non-coding RNA.

Presence of MHC-I in rat glioma cells expressing antisense IGF-I-receptor RNA.

J. Nikliński, L. Chyczewskî, J. Trojan., 2004, Roczniki Akademii Medycznej w Bialymstoku.

Studies of hepatocyte growth factor in bronchoalveolar lavage fluid in chronic interstitial lung diseases.

G. Przybylski, E. Wedrowska, P. Kopinski, 2015, Polskie Archiwum Medycyny Wewnetrznej.

Enhanced expression of Fas Ligand (FasL) in the lower airways of patients with fibrotic interstitial lung diseases (ILDs).

G. Przybylski, Tomasz Wandtke, P. Kopinski, 2012, Folia histochemica et cytobiologica.

FOLIA HISTOCHEMICA ET CYTOBIOLOGICA

K. Sladek, P. Kopinski, J. Szczeklik, 2007 .

Genetic biomarkers in lung cancer therapy - an update

J. Chorostowska-Wynimko, A. Szpechcinski, 2009 .

Reliable detection of rare mutations in EGFR gene codon L858 by PNA-LNA PCR clamp in non-small cell lung cancer.

T. Orlowski, J. Chorostowska-Wynimko, R. Langfort, 2013, Advances in experimental medicine and biology.

Quantitative analysis of free-circulating DNA in plasma of patients with resectable NSCLC

J. Kowalewski, T. Orlowski, J. Chorostowska-Wynimko, 2012, Expert opinion on biological therapy.

Antisense strategy in malignant brain tumours treatment.

L. Chyczewskî, J. Trojan., P. Kopinski, 2004, Roczniki Akademii Medycznej w Bialymstoku.

Targeted Next-Generation Sequencing of Thymic Epithelial Tumours Revealed Pathogenic Variants in KIT, ERBB2, KRAS, and TP53 in 30% of Thymic Carcinomas

M. Szołkowska, U. Lechowicz, A. Szpechcinski, 2022, Cancers.

[Molecular diagnostics of alpha-1-antitrypsin deficiency in clinical practice].

J. Chorostowska-Wynimko, A. Szpechcinski, R. Struniawski, 2008, Pneumonologia i alergologia polska.

Rapid DNA extraction protocol for detection of alpha-1 antitrypsin deficiency from dried blood spots by real-time PCR.

J. Chorostowska-Wynimko, A. Szpechcinski, M. Skroński, 2013, Advances in experimental medicine and biology.

Evaluation of fluorescence-based methods for total vs. amplifiable DNA quantification in plasma of lung cancer patients.

K. Roszkowski, M. Chabowski, T. Orlowski, 2008, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

miRNAs as Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer: Current Perspectives

J. Chorostowska-Wynimko, Mateusz Florczuk, Adam Szpechcinski, 2017, Targeted Oncology.

[Current methods to detect EGFR gene mutations as predictive factor for targeted therapies in non-small cell lung cancer - is there a "golden standard" in diagnostics?].

J. Chorostowska-Wynimko, A. Szpechcinski, M. Skroński, 2014, Pneumonologia i alergologia polska.

Molecular evidence of Anaplasma phagocytophilum and Babesia microti co-infections in Ixodes ricinus ticks in central-eastern region of Poland.

H. Sytykiewicz, P. Czerniewicz, I. Sprawka, 2012, Annals of agricultural and environmental medicine : AAEM.

Current perspectives on the use of miRNA as a biomarker for EGFR-targeted therapy for non-small cell lung cancer

J. Chorostowska-Wynimko, M. Florczuk, A. Szpechcinski, 2017 .

Coexistence of Borrelia burgdorferi s.l. genospecies within Ixodes ricinus ticks from central and eastern Poland

H. Sytykiewicz, P. Czerniewicz, I. Sprawka, 2015, Acta Parasitologica.

Real-time PCR quantification of plasma DNA in non-small cell lung cancer patients and healthy controls

P. Kopinski, J. Kowalewski, J. Chorostowska-Wynimko, 2009, European journal of medical research.

Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease

P. Śliwiński, T. Orlowski, J. Chorostowska-Wynimko, 2015, British Journal of Cancer.

The impact of genetic markers on the diagnosis of lung cancer: a current perspective.

J. Chorostowska-Wynimko, A. Szpechcinski, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The expression of circulating miR-504 in plasma is associated with EGFR mutation status in non-small-cell lung carcinoma patients

T. Orlowski, J. Chorostowska-Wynimko, R. Langfort, 2019, Cellular and Molecular Life Sciences.

Neoadjuvant therapy affects tumor growth markers in early stage non-small-cell lung cancer

M. Chabowski, K. Roszkowski-Śliż, T. Orlowski, 2009, European journal of medical research.

Immunohistochemistry versus DNA testing for detection of EGFR mutations and ALK rearrangements in lung adenocarcinoma patients

J. Chorostowska-Wynimko, R. Langfort, A. Szpechcinski, 2014 .

Plasma cell-free DNA levels and integrity in patients with chest radiological findings: NSCLC versus benign lung nodules.

T. Orlowski, J. Chorostowska-Wynimko, R. Langfort, 2016, Cancer letters.

Clinical significance of TP53 alterations in advanced NSCLC patients treated with EGFR, ALK and ROS1 tyrosine kinase inhibitors: An update.

J. Moes-Sosnowska, A. Szpechcinski, Joanna Chorostowska-Wynimko, 2023, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for Druggable EGFR Variants in Non-Small-Cell Lung Cancer

J. Moes-Sosnowska, M. Szołkowska, U. Lechowicz, 2024, International journal of molecular sciences.